Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Abstract Background Endocrine resistance is a major challenge in treating patients with ER+ /HER2− metastatic breast cancer (MBC) necessitating a switch from endocrine therapy to more toxic therapies. Mutations in ESR1 constitute a key mechanism of resistance to endocrine therapy in ER+ /HER2− BC. T...

全面介紹

書目詳細資料

Principais autores:	Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin
格式:	Artigo
語言:	Inglês
出版:	BMC 2025-07-01
叢編:	Breast Cancer Research
主題:	Complete estrogen receptor antagonist Selective estrogen receptor degrader Estrogen receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer Endocrine therapy Palazestrant Estrogen receptor mutation
在線閱讀:	https://doi.org/10.1186/s13058-025-02049-y
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!